Stimulants

The Lozenges That Are Redefining the Pick-Me-Up

Retrieved on: 
Thursday, February 25, 2021
Articles, Psychoactive drugs, Caffeine, Mutagens, Stimulants, Xanthines, Energy

Adults around the world are constantly looking for ways to increase their blood flow, concentration, and overall physical and mental energy.

Key Points: 
  • Adults around the world are constantly looking for ways to increase their blood flow, concentration, and overall physical and mental energy.
  • is offering a unique solution in the form of his Natural Energy Lozenges.
  • The result was Natural Energy Lozenges that delivered a punchy quantity of energy with clean ingredients, and without depending on caffeine or sugar to provide a pick-me-up.
  • Natural Energy is currently struggling to keep up with demand as orders continue to pour in through its various online outlets.

Worldwide Industry for Tobacco to 2026 - Featuring Swedish Match, Eastern Company and Imperial Brands Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 24, 2021
Tobacco, Retail, Psychoactive drugs, Stimulants, Asia, Cigarettes, Entheogens, Leaves, Tobacco, ITC Limited, Flue-cured tobacco, Paan, Cultivation of tobacco

The Global Tobacco Market size is expected to reach $1,066.6 billion by 2026, rising at a market growth of 3.6% CAGR during the forecast period.

Key Points: 
  • The Global Tobacco Market size is expected to reach $1,066.6 billion by 2026, rising at a market growth of 3.6% CAGR during the forecast period.
  • Irrespective of the fact that tobacco causes serious harm to the health, tobacco industry is still booming due to its economic importance.
  • Due to this factor, manufacturers are planning to launch premium tobacco products added with flue-cured tobacco and fine whole leaf.
  • Four largest tobacco companies in the world are China National Tobacco Corporation, PT GudangGaramTbk, Japan Tobacco Inc., and ITC Limited are from Asia-Pacific.

Noven Submits New Drug Application for Investigational Dextroamphetamine Transdermal System for ADHD

Retrieved on: 
Monday, February 22, 2021
FDA, General Health, Pharmaceutical, Health, Psychoactive drugs, Drugs, Health sciences, Substituted amphetamines, Stimulants, Ergogenic aids, Phenethylamines, Transdermal patch, Hisamitsu Pharmaceutical, Amphetamine, New Drug Application, Food and Drug Administration

Noven Pharmaceuticals, Inc., (Noven) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today confirmed it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system (ATS).

Key Points: 
  • Noven Pharmaceuticals, Inc., (Noven) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today confirmed it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system (ATS).
  • Currently, there is no amphetamine-based transdermal treatment option available for ADHD.
  • The NDA submission is supported by results from a multicenter, laboratory classroom study which evaluated the safety and efficacy of ATS in over 100 pediatric patients with ADHD.
  • Novens mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery.

Altitude Boosts Energy With Less Caffeine

Retrieved on: 
Monday, January 25, 2021
Drinks, Psychoactive drugs, Energy drinks, Food and drink, Caffeine, Mutagens, Stimulants, Xanthines, Coffee, Four Loko, V, Caffeine dependence

It's a problem that the European-based brand PilotsFriend is aiming to address with its popular product Altitude.

Key Points: 
  • It's a problem that the European-based brand PilotsFriend is aiming to address with its popular product Altitude.
  • This dependence on natural caffeine for a slow, steady, and long-lasting source of energy allowed PilotsFriend West Inc. to use minimal quantities of caffeine in the drink itself.
  • In fact, each can of Altitude has significantly less caffeine than your average cup of coffee, coming in at a mere 48mg total.
  • About Altitude: Altitude is an American offshoot of the European brand PilotsFriend.

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

Retrieved on: 
Wednesday, January 20, 2021
Psychoactive drugs, Branches of biology, Drugs, Entheogens, TAAR1 agonists, Hallucinations, Euphoriants, MDMA, Stimulants, Lysergic acid diethylamide, Psychedelic drug, Serotonin

MindMed is undertaking a Phase 1 clinical trial to evaluate if MDMA, when balanced and used in combination with LSD, can help offset some of the known potential unpleasant effects of LSD that occur in therapy or clinical settings.

Key Points: 
  • MindMed is undertaking a Phase 1 clinical trial to evaluate if MDMA, when balanced and used in combination with LSD, can help offset some of the known potential unpleasant effects of LSD that occur in therapy or clinical settings.
  • MindMed is interested in understanding how to balance both MDMA and LSD in a cohesive way to create better patient outcomes, and develop more advanced psychedelic assisted therapies, as MindMed expands both its R&D and commercial drug development pipeline.
  • LSD in other Phase 1 clinical trials has demonstrated an acute subjective effect on the serotonin 5-HT2A receptor stimulation, leading to ego dissolution and neuroplasticity.
  • If MindMed finds the Phase 1 trial results promising, it will work with expert clinicians to undertake patient studies with treatments combining MDMA and LSD for various potential indications and mental disorders.

Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting

Retrieved on: 
Tuesday, January 19, 2021
Drugs, Branches of biology, Clinical medicine, Amphetamine, Stimulants, Nootropics, Anorectics, Substituted amphetamines, Attention deficit hyperactivity disorder, Nasal administration, Medroxyprogesterone acetate, Magnesium in biology

There remains a clear unmet need for products that can treat ADHD effectively while attending to the significant problem of stimulant misuse.

Key Points: 
  • There remains a clear unmet need for products that can treat ADHD effectively while attending to the significant problem of stimulant misuse.
  • The first study enrolled 24 subjects and was designed to compare the PK of d-AMPH from ADAIR 10 mg to IR d-AMPH 10 mg administered orally.
  • The primary PD endpoint demonstrated manipulated intranasal ADAIR had significant reduction in drug liking (p
  • All other PD endpoints reflected abuse-deterrent properties for intranasal ADAIR relative to intranasal d-AMPH (e.g., Take Drug Again, High, Subjective Drug Value).

Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy and Safety Data at the 2021 APSARD Annual Meeting

Retrieved on: 
Friday, January 15, 2021
Drugs, Psychoactive drugs, Health sciences, Substituted amphetamines, Anorectics, Ergogenic aids, Phenethylamines, Stimulants, Amphetamine, Medication, Pharmaceutical industry, Attention deficit hyperactivity disorder management

The presentation, "Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of the Amphetamine Extended-Release Tablet in Adults with Attention-Deficit/Hyperactivity Disorder," provides original data about the efficacy and safety of the new tablet formulation.

Key Points: 
  • The presentation, "Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of the Amphetamine Extended-Release Tablet in Adults with Attention-Deficit/Hyperactivity Disorder," provides original data about the efficacy and safety of the new tablet formulation.
  • This presentation will be delivered during the Scientific Poster Session on Friday, January 15, 2021 from 6:007:30 PM EST.
  • This new amphetamine extended-release tablet is an investigational agent and is not currently approved for use in any country.
  • Tris Pharma is a New Jersey-based specialty pharmaceutical company focused on the development and commercialization of innovative medicines that address unmet patient needs.

Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Retrieved on: 
Friday, January 15, 2021
Psychoactive drugs, Drugs, Clinical research, Design of experiments, Entheogens, MDMA, Stimulants, Clinical trial, Placebo-controlled study, MDMA-assisted psychotherapy, Multidisciplinary Association for Psychedelic Studies

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction Treatment

Key Points: 
  • Awakn's Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical trial designed to investigate the safety and efficacy of MDMA as a pharmacological treatment for Alcohol Use Disorder.
  • While there are current treatment methods available, which are effective for some segments of the population, relapse rates are high.
  • Principal investigator for the Phase II trial will be Dr. Ben Sessa, Chief Medical Officer of Awakn, who previously led the world's only MDMA and AUD study.
  • Awakn Life Sciences is a biotechnology company focused on the research, development, and delivery of psychedelic medicines for the treatment of mental health conditions.

KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference

Retrieved on: 
Thursday, January 14, 2021
Psychoactive drugs, Stimulants, Food and Drug Administration, Nootropics, Methylphenidate, Norepinephrine-dopamine reuptake inhibitors, Prescription Drug User Fee Act, Attention deficit hyperactivity disorder, New Drug Application, Drug, Dexmethylphenidate, Attention deficit hyperactivity disorder management

The 2021 APSARD Virtual Conference (APSARD 2021) is being be held January 15-17, 2021.

Key Points: 
  • The 2021 APSARD Virtual Conference (APSARD 2021) is being be held January 15-17, 2021.
  • KP415 is KemPharms investigational product candidate for the treatment of attention deficit hyperactivity disorder (ADHD).
  • Serdexmethylphenidate (SDX) is KemPharms prodrug of d-methylphenidate (d-MPH).
  • A New Drug Application (NDA) for KP415 is currently under review with the U.S. Food and Drug Administration (FDA) with an anticipated PDUFA date of March 2, 2021.

KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”

Retrieved on: 
Wednesday, January 13, 2021
Psychoactive drugs, Stimulants, Euphoriants, Nootropics, Piperidines, Phenethylamines, Methylphenidate, Benzhydrocodone, Dexmethylphenidate, Attention deficit hyperactivity disorder, Serdexmethylphenidate, Hydrocodone

KP415 consists of serdexmethylphenidate (SDX), KemPharms prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.

Key Points: 
  • KP415 consists of serdexmethylphenidate (SDX), KemPharms prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.